obesity drugs
The latest news about obesity drugs: headlines, AI summaries and the full story from every source.
- Amgen Develops Monthly Obesity Drug MariTide to Challenge Weekly Injection Market
- Novo Nordisk CEO Provides Timeline for CagriSema Obesity Drug Launch
- Novo Nordisk Raises 2026 Outlook Amid Strong Obesity Drug Sales but Declines 2027 Guidance
- Eli Lilly Raises Price Target Amid Strong Third Quarter Earnings and Obesity Drug Growth
- Eli Lilly Set to Report Third-Quarter Earnings Driven by Obesity and Diabetes Drugs
- Novo Nordisk's CagriSema Shows 25% Weight Loss in Phase 3 Clinical Trial
- Eli Lilly's Upcoming Earnings Report and the Significance of Retatrutide
- Novo Nordisk Announces Two Major Licensing Deals Worth Nearly $4 Billion
- Eli Lilly and Novo Nordisk Develop Amylin-Based Obesity Drugs as Complement or Alternative to GLP-1s
- Novo Nordisk outlines growth strategy amid Eli Lilly's expanding GLP-1 lead
- Viking Therapeutics' Obesity Drug Trial Results Spark Market Interest
- Viking Therapeutics Surges on Positive GLP-1 Maintenance Dosing Data
- Eli Lilly CEO Highlights Growth Drivers for Obesity Drug Market
- Eli Lilly CEO Reports Strong Adoption of GLP-1 Medications Among New Senior Patients
- Novo Nordisk Shares Drop as Post-Wegovy Growth Strategy Fails to Alleviate Competition Concerns
- Novo Nordisk Shares Drop as Investors Disappointed by Vague Turnaround Strategy
- Novo Nordisk Rebrands as Novo and Partners with Anthropic to Accelerate Drug Discovery in Diabetes and Obesity
- Novo CEO Announces Strategic Shift in Obesity Market Approach
- Novo Nordisk Rebrands as 'Novo' in Strategic Move to Counter Eli Lilly's Growth
- Eli Lilly Captures Over 30% of New U.S. Patients on Oral Weight-Loss Medications
- Novo Nordisk Rebrands to 'Novo' Amid Obesity Market Competition
- Eli Lilly Acquires Merida Biosciences for $2.88 Billion to Expand into Autoimmune Diseases
- Ken Griffin Increases Stake in Eli Lilly Amid Strong Performance
- Eli Lilly and Novo Nordisk Compete in Growing Weight-Loss Pills Market
- Novo Nordisk Seeks Injunction to Block Eli Lilly Weight-Loss Drug Ads
- Novo Nordisk Sues Eli Lilly Over Alleged Misleading Advertising Campaign
- Novo Nordisk Sues Eli Lilly Over Alleged Misleading GLP-1 Drug Advertising
- Viking Therapeutics Announces Phase 1 Trial for Weight Loss Drug Targeting Amylin and Calcitonin Pathways
- Medicare's New Obesity Drug Coverage Launches on July 1 with Low Copay
- Johnson & Johnson CEO Announces Company Will Not Enter Obesity Drug Market
- Eli Lilly's Obesity Drug Sales Face Medicare Access Test
- Eli Lilly Stock Hits Record High on Positive Clinical Trial Results for Weight Loss Drug
- Eli Lilly Achieves Coverage of All Obesity Medicines by Major U.S. Pharmacy Benefit Managers
- CVS Health Restores Coverage for Eli Lilly’s Zepbound and Adds Obesity Pill
- Novo Nordisk Reports High-Dose Wegovy Achieves Nearly 28% Weight Loss in Some Patients
- Eli Lilly Stock Reacts to FDA Liver Failure Report for Foundayo
- Novo Nordisk Raises Outlook Slightly as Q1 Profit Exceeds Forecast
- Pfizer Outlines Post-2028 Growth Strategy Focused on Obesity Drugs
- Pfizer Outperforms Moderna in Post-COVID Earnings
- Eli Lilly Investors Await Foundayo Launch Data Amid Market Uncertainty
- Eli Lilly's Obesity Drug Shows Modest Growth as Competition with Novo Nordisk Intensifies